MedTrace Logo

Topical Antifungal Treatment for Tinea Cruris

NCT01342315 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 483

Last updated 2013-08-28

No results posted yet for this study

Summary

To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris

Conditions

  • Tinea Cruris

Interventions

DRUG

33525

Daily dosing

DRUG

Placebo

Daily dosing

Sponsors & Collaborators

  • Medicis Global Service Corporation

    lead INDUSTRY

Principal Investigators

  • Ron Staugaard · Medicis Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-03-31
Completion
2012-05-31

Countries

  • United States
  • Belize
  • El Salvador
  • Honduras
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342315 on ClinicalTrials.gov